Triple negative breast cancer: unmet medical needs

Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer

(2010) Daniel P. Silver et al.   JOURNAL OF CLINICAL ONCOLOGY

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

(2010) M. Elizabeth H. Hammond et al.   JOURNAL OF CLINICAL ONCOLOGY

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

(2010) Andrew Tutt et al.   LANCET

Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers

(2009) Sharon Nofech-Mozes et al.   BREAST CANCER RESEARCH AND TREATMENT

Breast Cancer Subtypes as Defined by the Estrogen Receptor (ER), Progesterone Receptor (PR), and the Human Epidermal Growth Factor Receptor 2 (HER2) among Women with Invasive Breast Cancer in California, 1999-2004

(2009) Carol A. Parise et al.   Breast Journal

Cancer Statistics, 2009

(2009) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics

(2009) B. T. Hennessy et al.   CANCER RESEARCH

Survival Outcomes for Patients with Metastatic Triple-Negative Breast Cancer: Implications for Clinical Practice and Trial Design

(2009) Farrah Kassam et al.   Clinical Breast Cancer

Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial

(2009) Judith Hugh et al.   JOURNAL OF CLINICAL ONCOLOGY

Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy

(2009) Tomasz Byrski et al.   JOURNAL OF CLINICAL ONCOLOGY

Triple-negative breast cancer: Novel therapies and new directions

(2009) Sumanta Kumar Pal et al.   MATURITAS

Platinum-based chemotherapy in triple-negative breast cancer

(2008) B. Sirohi et al.   ANNALS OF ONCOLOGY

Pattern of metastatic spread in triple-negative breast cancer

(2008) Rebecca Dent et al.   BREAST CANCER RESEARCH AND TREATMENT

Triple-Negative Breast Cancer: Risk Factors to Potential Targets

(2008) B. P. Schneider et al.   CLINICAL CANCER RESEARCH

Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: A dose-escalation study

(2008) Chris Twelves et al.   EUROPEAN JOURNAL OF CANCER

Basal-like subtype and BRCA1 dysfunction in breast cancers

(2008) Yasuo Miyoshi et al.   International Journal of Clinical Oncology

Clinical and Pathologic Characteristics of Patients WithBRCA-Positive andBRCA-Negative Breast Cancer

(2008) Deann P. Atchley et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

(2008) Harold J. Burstein et al.   JOURNAL OF CLINICAL ONCOLOGY

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

(2008) Cornelia Liedtke et al.   JOURNAL OF CLINICAL ONCOLOGY

Resistance to therapy caused by intragenic deletion in BRCA2

(2008) Stacey L. Edwards et al.   NATURE